Dasatinib

Well-established oncology drug. The dasatinib + quercetin senolytic combination shows promise in early human trials for age-related conditions, but longevity data is preliminary.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Robust Phase III oncology data for CML and ALL. Senolytic research: the D+Q combination cleared senescent cells and improved physical function in open-label trials of idiopathic pulmonary fibrosis and diabetic kidney disease. Mechanism involves inhibition of survival pathways (BCR-ABL, SRC family, ephrin receptors) that senescent cells depend on.

• FDA-approved for CML and Ph+ ALL
• Demonstrated senescent cell clearance in early human trials
• Improved physical function in senolytic pilot studies

Oncology: 100–140 mg/day. Senolytic protocol: 100 mg dasatinib + 1000 mg quercetin for 3 consecutive days per month (investigational).

• Pleural effusion
• Myelosuppression
• Nausea
• Diarrhea
• Pulmonary arterial hypertension

Serious oncology-grade side effects including pleural effusion, myelosuppression, and pulmonary hypertension. Senolytic dosing is intermittent but still carries risk. Not for unsupervised self-experimentation.

Senolytic trials are small, open-label, and short-term. Using a chemotherapy agent for anti-aging requires careful risk-benefit analysis.

• Longevity45
• Immunity30